Novo Nordisk and Eli Lilly are likely to maintain their first-mover advantage in the rapidly growing weight loss drug category. Still, a new report by Morningstar and PitchBook analysts predicts that, by 2031, newcomers will command $70 billion of the GLP-1 market. Next-generation obesity drugs are coming from Roche, Amgen, Pfizer, and others. Drugmakers may press their advantage with acquisitions of privately held companies like Arch Venture Partners-backed Metsera or Bain Capital-backed Hercules.
Read the full article: Obesity Drugs: The Next Wave of GLP-1 Competition //
Source: https://pitchbook.com/news/reports/q3-2024-obesity-drugs-the-next-wave-of-glp-1-competition